PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer

Overcoming distant metastasis stands as a paramount challenge in enhancing the outcomes of breast Cancer treatments. Thus, delving deeper into comprehending the intricate mechanisms underlying breast Cancer metastasis becomes imperative, offering potential avenues for pioneering therapeutic approaches. PRMT6, an arginine N-methyltransferase, possesses the ability to methylate both histone and non-histone proteins. It has been reported that methylation of non-histone proteins impacts their cellular localization, stability, and activation, consequently influencing tumor progression. However, the extent to which PRMT6-mediated non-histone protein methylation influences Cancer cell metastasis, particularly in the context of breast Cancer, remains elusive. In this study, we established that PRMT6 exerted a positive regulatory influence on breast Cancer metastasis through both in vivo and in vitro experiments. Mechanistically, we innovatively revealed that PRMT6 asymmetrically di-methylated STAT3 at arginine 729 (STAT3 R729me2a). This modification proved indispensable for STAT3's membrane localization, its interaction with JAK2, STAT3 Y705 phosphorylation, and PRMT6-driven Cancer cell metastasis. From a clinical perspective, we unearthed the promising potential of STAT3 R729me2a as a robust prognostic marker for predicting the overall survival time of breast Cancer patients. In terms of therapeutic intervention, we demonstrated the significant capability of the PRMT6 Inhibitor, EPZ020411, to curtail breast Cancer metastasis both in vivo and in vitro. In sum, our study unveils the pivotal biological role of PRMT6-mediated STAT3 R729me2a in breast Cancer metastasis and underscores the prospective utility of PRMT6 inhibitors as effective therapeutic strategies against STAT3-driven metastatic breast Cancer.